Showing 1 - 10 out of 297 Results
FDA on October 27 announced the licensing of talimogene laherparepvec, the first oncolytic virus therapy cleared for marketing in the United States.
The Hospital Pharmacy Section of the International Pharmaceutical Federation (FIP) on September 10 released the newest version of statements describing the future of hospital pharmacy practice.
FDA today approved trabectedin for injection as a second-line treatment for unresectable or metastatic liposarcoma or leiomyosarcoma.
Pharmacists say automated dispensing cabinets (ADCs) can bring efficiencies to the care of patients in the emergency department (ED), but it's important to ensure that nurses aren't worried about being administratively locked out of the devices during a crisis.
FDA officials in October listened to feedback from the public and from invited speakers about how risk evaluation and mitigation strategy (REMS) programs affect the healthcare delivery system and patients' access to important medications.
FDA and Boehringer Ingelheim on October 16 announced the approval of idarucizumab injection to reverse the anticoagulant effects of dabigatran.
The old rallying call of independent pharmacies—"Get into politics or get out of pharmacy"—still holds true today and applies to all segments of the profession, said John M. Coster, the 2015 William A. Zellmer Lecturer.
The seemingly common practice at pharmacies and outsourcing facilities of storing sterile compounded preparations or repackaging sterile pharmaceuticals in drug-administration syringes is actually an unapproved use of these medical devices, according to FDA.
Asfotase alfa, a tissue nonspecific alkaline phosphatase produced by recombinant DNA technology, was approved by FDA on October 23 and, according to manufacturer Alexion Pharmaceuticals Inc., is now commercially available.
Showing 1-10 of 297
- OF 30